Clinical Characteristics and Severity of COVID-19 Disease in Patients from Boston Area Hospitals

Background

The incidence of COVID-19 in Massachusetts has been near exponential, ranking third nationwide with more than 66,000 confirmed case. Partners HealthCare, which includes several large Boston-area hospitals, has reported 4,140 COVID-19 patients as of April 18, 2020. We summarize key demographic, clinical, and medical characteristics of these patients with respect to the severity of COVID-19 disease.

Methods

The Partners Electronic Health Record (EHR) contains outpatient and inpatient records for >4 million patients mostly from greater Boston, Massachusetts. The patient population in this study includes all patients (N=4,140) with at least one positive or presumptive positive COVID-19 test result¹ documented in the Partners EHR between December 1, 2019 and April 18, 2020. The study was approved by the Partners Institutional Review Board. Laboratory, clinical, and medical records (April 1, 2015-April 18, 2020) were obtained from the Partners Research Patients Data Registry (RPDR) and the Enterprise Data Warehouse (EDW)^2-4. All data was updated daily, except for prior conditions which are updated annually using a machine learning algorithm⁴. Income data was linked to the 2018 US Census. Medication use was coded as ever in 2015-2020. Severity was defined in five mutually exclusive categories (I) outpatients only, (II) evaluation in an emergency department without admission, (III) inpatient admission not requiring intensive care unit (ICU) care, (IV) inpatient admission requiring ICU care, and (V) deceased.

Two-sided tests of trend were performed unless otherwise noted. Python and R software languages were used. All data were obtained from Electronic Health Records Repository Maintained by Brigham Mass General HealthCare Systems in full compliance with the IRB protocols and met all data access requirements. Obtaining consent from all individuals would make the study challenging logistically, financially and scientifically, especially due to the urgent nature of the pandemic.

Results

Out of 4,140 COVID-19 patients (55% women, median age 52 years (interquartile range: 36-65)), two thirds (N: 2,759) were outpatients, including 795 (19% of the COVID-19 patients) who were evaluated in an outpatient emergency department. Of the 1,194 inpatients, 619 (15% of the COVID-19 patients) were admitted to a Partners hospital but not to the ICU, while 575 (13.9%) were admitted to the ICU, and 187 (4.5%) died in-hospital. Older age, male sex, and comorbidities were more prevalent according to COVID-19 severity (Table). Prevalence of current/ever smoking was greater by severity (p-value < 2.2e- 16), and this group accounted for 58.3% of the deceased patients. Median household income per zip code had nonlinear association with severity. Table shows comorbidities and medication use according to severity. The most prevalent comorbidities among deceased patients were hyperlipidemia, hypertension, prior pneumonia (p-values < 2.2e-16 from the test of trend). Multiple other comorbidities also tracked with the disease severity. Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers was also greater by severity, but so was use of cardiovascular and other medications including other antihypertensives, statins, antiplatelets, direct oral anticoagulants, antidiabetic medications and vitamin D3.

Discussion

In this large greater Boston study of 4,140 patients, multiple comorbidities and greater use of medications tracked with the severity of COVID-19. The data sources used in this study were limited to the use of the EHR. We found that prior use of antihypertensive medications as well as lipid lowering and other cardiovascular drugs such as direct oral anticoagulants and antiplatelets all tracked with increased severity of COVID-19 and should be further investigated with appropriate adjustment for confounders⁵. Common prior comorbidities including hyperlipidemia, hypertension, and pneumonia also tracked with increased severity.

Footnotes

Authors of this manuscript have no conflicts of interest to declare.

Funding

This work was supported by the National Heart Lung and Blood Institute [T32 HL007575 to H.D., R01 HL134811; K24 HL136852; and HL 117861 to S.M., 5K01HL135342 to O.D.], and by philanthropic support from the Brigham COVID fund.